Introduction

The needle was always the problem. Wegovy, Mounjaro, Zepbound — all weekly injections. For millions of people, that was enough to walk away.

On April 1, 2026, Eli Lilly changed that. The FDA approved Foundayo (orforglipron): a once-daily GLP-1 pill you take any time of day, with or without food, no injection required. Available now at US pharmacies for $149/month.

The same company also has retatrutide, which as of August 2026 has completed all four core Phase 3 trials — a weekly injection that produces nearly three times more weight loss than Foundayo in its cleanest comparison. Realistic FDA approval falls between late 2027 and mid-2028.

Two drugs from the same manufacturer. One available today, one still a year or more away. One affordable and convenient, one dramatically more effective. The question isn't which is better — it's which is right for you, and when.

How Retatrutide and Foundayo (Orforglipron) Compare

The core trade-off is simple: retatrutide is dramatically more effective but doesn't exist as a prescription yet. Foundayo is less effective but is available, affordable, and requires no injection.

Weight Loss Results: 28.3% vs 11.2% — What the Phase 3 Data Shows

Retatrutide (TRIUMPH trials)

TRIUMPH-4 (68 weeks, obesity + osteoarthritis, n=445): 28.7% average weight loss at 12mg dose.

TRIUMPH-1 (80 weeks, general obesity, n=2,339): 28.3% average weight loss at 12mg dose. A prespecified 104-week extension in the BMI ≥35 subgroup showed continued loss reaching 30.3% — with no plateau at 80 weeks.

Secondary endpoints (TRIUMPH-1): 45.3% of patients achieved ≥30% weight loss. 65.3% reached a BMI below 30.

As of August 2026, retatrutide's two remaining core trials have also completed: TRIUMPH-2 (obesity + type 2 diabetes, 1,152 participants, 20.8% weight loss) and TRIUMPH-3 (obesity + established cardiovascular disease, 1,949 participants, 22.6% weight loss), both confirmed July 23, 2026. These lower — but still substantial — results in more complex populations don't change the headline comparison against Foundayo above, since Foundayo's own trials (ATTAIN-1/2) similarly show somewhat lower results in patients with diabetes. For the full breakdown of all four TRIUMPH trials, see our complete clinical results guide.

Foundayo / Orforglipron (ATTAIN trials)

ATTAIN-1 (72 weeks, obesity without diabetes, n=3,127): 7.5–11.2% weight loss across doses. At the highest dose (equivalent to FDA-approved 17.2mg), participants who stayed on treatment for the full 72 weeks lost an average of 12.4% (~27 lbs).

ATTAIN-2 (72 weeks, obesity with type 2 diabetes): 10.5% weight loss at the highest dose.

Retatrutide vs Foundayo: How Much More Weight Do You Lose?

‍
Note: Direct trial comparisons are limited by differences in study design, populations, and duration. Retatrutide's higher weight loss partly reflects its triple mechanism and may also reflect population differences.

Retatrutide produces roughly 2.5x more weight loss than Foundayo. That is a clinically meaningful difference. For someone starting at 300 lbs:

• Foundayo: ~33 lbs lost
• Retatrutide: ~85 lbs lost

Why Retatrutide Causes 2.5x More Weight Loss Than Foundayo

How Foundayo (Orforglipron) Works: GLP-1 Receptor Only

Foundayo activates a single receptor: GLP-1. This is the same mechanism as semaglutide (Wegovy, Ozempic). GLP-1 activation slows gastric emptying, reduces appetite, and stimulates insulin release.

What makes Foundayo different from Wegovy isn't the mechanism — it's the format. Foundayo is a small molecule (non-peptide), which means it can be taken orally without food restrictions. Wegovy's oral form (semaglutide tablets) must be taken on an empty stomach with minimal water.

Weight loss ceiling for GLP-1 only: approximately 12–15% based on current data.

How Retatrutide Works: Triple Agonist (GLP-1 + GIP + Glucagon)

Retatrutide simultaneously activates three receptors:

• GLP-1: appetite suppression, slows gastric emptying
• GIP: enhances GLP-1 effects, improves tolerability, may affect fat storage
• Glucagon: increases metabolic rate, enhances fat burning, reduces liver fat

The glucagon component is what makes retatrutide unique. No other approved obesity medication activates glucagon receptors at meaningful levels. This additional mechanism drives the dramatically higher weight loss — and is also responsible for retatrutide's unique side effect: dysesthesia (abnormal skin sensations in 20.9% at 12mg in TRIUMPH-4, 12.5% in TRIUMPH-1).

For a complete explanation of retatrutide's mechanism and trial data, see our complete retatrutide guide.

Side Effects: What to Expect from Each Medication

Foundayo Side Effects

Common (occurring most often during dose escalation):

• Nausea
• Constipation
• Diarrhea
• Vomiting
• Indigestion / abdominal pain
• Hair loss (noted more than with injectable GLP-1s)

Discontinuation due to adverse events: 5.3–10.3% depending on dose, vs 2.7% placebo (ATTAIN-1).

No unique side effects — the profile is consistent with other GLP-1 medications. No dysesthesia. No injection site reactions.

One key advantage: because Foundayo is a small molecule taken orally, GI side effects may be somewhat different in character from injectable GLP-1s, but the overall tolerability profile is similar.

Retatrutide Side Effects

Common:

• Nausea: ~43% at 12mg (TRIUMPH-4)
• Diarrhea: ~33%
• Vomiting: ~20%
• Dysesthesia: 20.9% at 12mg in TRIUMPH-4, 12.5% in TRIUMPH-1 (abnormal skin sensations — unique to retatrutide)

Discontinuation due to adverse events: 11.3% (TRIUMPH-1, general obesity) / 18.2% (TRIUMPH-4, osteoarthritis population).

For detailed information on managing retatrutide side effects, see our retatrutide side effects guide.

Side Effect Comparison: Retatrutide vs Foundayo

‍
Tolerability verdict: Foundayo has a somewhat better tolerability profile. No dysesthesia, lower discontinuation rates, no injections. For patients who struggle with needles or who are sensitive to side effects, this matters.

Cost and Availability: What Each Medication Actually Costs

Foundayo — Available Now

• Self-pay: $149/month (all doses, self-pay)
• With commercial insurance: as low as $25/month with Lilly savings card
• Medicare Part D: $50/month beginning July 1, 2026
• Available at US retail pharmacies, LillyDirect, and telehealth providers
• Approved April 1, 2026 — on shelves now

This pricing is a major disruption. At $149/month self-pay, Foundayo is dramatically cheaper than Wegovy (~$1,350/month) or Zepbound (~$1,060/month). Lilly appears to be pursuing market share aggressively with accessible pricing.

Retatrutide — Not Yet Available

Retatrutide pricing is unknown. Based on comparable injectables (Zepbound: ~$1,060/month) and higher efficacy, expect $1,200–1,500/month before insurance. Lilly's aggressive pricing of Foundayo may signal a willingness to be competitive, but retatrutide's superior efficacy could also justify premium pricing. For a full breakdown of retatrutide cost expectations and insurance strategies, see our complete cost guide.

All four core Phase 3 trials are now complete. Eli Lilly is expected to submit a Biologics License Application (BLA) — not an NDA, since retatrutide is a biologic — in Q1 2027. Realistic FDA approval falls between Q3 2027 (priority review) and Q1–Q2 2028 (standard review), with commercial launch following 1–3 months later — late 2027 to mid-2028.

For the most current retatrutide approval timeline, see our when retatrutide will be available page.

Who Should Consider Foundayo Now?

Waiting a year or more for a drug that isn't approved yet isn't an option for everyone. If any of the following apply, Foundayo is worth starting now:

• Your health can't wait until 2027 or 2028. Obesity-related complications — hypertension, prediabetes, sleep apnea, joint pain — worsen over time. Starting treatment today with Foundayo is better than waiting for a theoretically superior drug.
• Needles are a genuine barrier. Not discomfort — a real reason you won't comply with weekly injections. Foundayo at 11% weight loss is infinitely more effective than retatrutide you never take.
• 10–15% weight loss solves your problem. Going from BMI 33 to BMI 28 doesn't require 28% weight loss. Foundayo can get you there.
• Cost matters. At $149/month self-pay — a fraction of Wegovy or Zepbound — Foundayo is accessible to patients who can't afford or don't qualify for injectable coverage. Retatrutide will almost certainly cost more.

One more reason to consider starting now: the ATTAIN-MAINTAIN trial showed patients who plateaued on semaglutide or tirzepatide and switched to orforglipron maintained their weight loss. Foundayo can serve as a bridge — effective treatment today, with the option to transition to retatrutide when it's approved.

Who Should Wait for Retatrutide?

For some patients, 11% weight loss isn't the goal — it's not even close to enough. If that's you, waiting for retatrutide is the right call:

• Severe obesity (BMI ≥40). Going from 350 lbs to 311 lbs (11%) leaves you still severely obese. Going from 350 lbs to 251 lbs (28%) changes your metabolic trajectory entirely. These are not comparable outcomes.
• Multiple complications that need simultaneous treatment. Retatrutide's TRIUMPH-4 trial showed 28.7% weight loss alongside 75.8% improvement in knee pain, significant blood pressure reduction, and HbA1c normalization — all at once. No other medication delivers this.
• You've already failed a GLP-1. If Wegovy gave you inadequate weight loss, Foundayo — another pure GLP-1 — is unlikely to perform dramatically differently. Retatrutide's glucagon component offers a genuinely different mechanism.
• You're building an insurance case. Documenting a trial-and-failure of Foundayo (or other GLP-1s) now could strengthen your prior authorization for retatrutide later. This is strategic, not a waste of time.
• Injections aren't an issue. If you're already taking Ozempic or Mounjaro, the weekly injection is not a barrier. There's no reason to accept lower efficacy for a format you don't need.

Start Foundayo Now, Switch to Retatrutide Later: A Practical Strategy

One approach worth considering: start with Foundayo now, transition to retatrutide when available.

The data supports this. ATTAIN-MAINTAIN showed patients could switch from injectable GLP-1s to orforglipron and maintain weight loss. Going in the other direction — from Foundayo to retatrutide — should theoretically work similarly, with the expectation of additional weight loss from the more potent medication.

Practical steps if pursuing this strategy:

1. Start Foundayo now (available, affordable)
2. Achieve initial weight loss over 12–18 months
3. When retatrutide receives FDA approval, switch to retatrutide for further weight loss or superior maintenance
4. Document inadequate response if needed for insurance — this establishes "trial and failure" history that strengthens retatrutide prior authorization

Which Medication Is Right for You? A Decision Framework

Choose Foundayo if: you need treatment now, weight loss of 10–15% is sufficient, needles are a barrier, or cost is a primary concern.

Wait for Retatrutide if: you have severe obesity, need maximum weight loss (28%+), have multiple complications, or have already tried pure GLP-1 medications without adequate response.

Consider both sequentially: start Foundayo now, transition to retatrutide when it becomes available for superior long-term results.

What Retatrutide and Foundayo Mean for Obesity Treatment in 2026–2028

The approval of Foundayo marks the beginning of a new era for obesity medicine. For the first time, patients can access a GLP-1 medication in pill form without meal restrictions, at a price point well below existing injectables.

But Foundayo's efficacy ceiling — roughly 11–12% average weight loss — leaves significant room for improvement. Retatrutide, if approved, will represent the most effective pharmaceutical option for obesity ever approved, with weight loss approaching bariatric surgery levels in some patients.

The next year and a half to two years will see both medications available simultaneously (retatrutide launching sometime between late 2027 and mid-2028). Patients and physicians will need to choose based on individual circumstances: the convenience and accessibility of Foundayo vs the superior efficacy of retatrutide.

Conclusion

Foundayo and retatrutide are not competing for the same patient. They never were.

Foundayo is for people who need treatment now — accessible, oral, affordable, with clinically meaningful weight loss for the right candidate. If that's you, there's no good reason to wait.

Retatrutide is for people who need more — more weight loss, more metabolic change, a medication that addresses obesity at a scale that approaches surgery. If that's you, it's worth understanding what's coming and preparing for it.

The most likely scenario for millions of patients: Foundayo first, retatrutide when it arrives. Not as a failure of the first drug — but as a logical progression as obesity medicine gives patients better and better options.

All four core TRIUMPH trials are now complete, and retatrutide's realistic approval window is late 2027 to mid-2028. For the latest on the full trial program and what happens next, see our complete retatrutide guide.

Sources

• Wharton S, et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine, 2025 (ATTAIN-1 trial)
• Eli Lilly press release: ATTAIN-2 Phase 3 topline results. 2025.
• Eli Lilly press release: ATTAIN-MAINTAIN Phase 3 results. December 18, 2025.
• FDA press release: Approval of Foundayo (orforglipron). April 1, 2026.
• Eli Lilly TRIUMPH-1 Phase 3 topline results, including 80-week and 104-week extension data. May 21, 2026.
• Eli Lilly TRIUMPH-4 Phase 3 topline results. December 2025.
• Eli Lilly press release: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials. July 23, 2026.
• Foundayo (orforglipron) prescribing information. Eli Lilly, 2026.